<DOC>
	<DOCNO>NCT02466009</DOCNO>
	<brief_summary>The purpose study measure high grade ( 3-5 ) toxicity regorafenib monitor impact treatment regorafenib quality life old adult metastatic colorectal cancer .</brief_summary>
	<brief_title>Regorafenib Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Subjects ask participate study age 70 old require treatment colorectal cancer spread part body get good treatment . Subjects undergo initial test ensure meet criterion necessary participate study . Once subject complete initial test meet eligibility criterion , subject begin treatment 120 mg regorafenib ( 3 tablet ) day 21 day ( 3 week ) 28 day cycle ( 4 week ) . After first cycle , doctor discus possibility increase dose 160 mg ( 4 tablet ) day 21 day ( 3 week ) 28 day cycle ( 4 week ) base subject health status . During study , assessment perform monitor subject tolerance response treatment . Regorafenib continue long subject tolerate treatment subject colorectal cancer either respond treatment remain stable .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histologically confirm colorectal adenocarcinoma Measurable metastatic disease . Age +/ &gt; 70 Progression standard therapy , candidate chemotherapy patient decline option Life expectancy &gt; /= 12 week Able understand willing sign write informed consent . Laboratory requirement : Total bili ≤ 1.5 x upper limit normal Alanine aminotransferase &amp; Asparate aminotransferase ≤ 2.5 x upper limit normal Serum creatinine ≤ 1.5 x upper limit normal International normalized ratio/prothrombin time ≤ 1.5 x upper limit normal Platelet count ≥ 100,000 , hemoglobin ≥ 9 g/dL Absolute neutrophil count ≥ 1,500 . Blood transfusion meet inclusion criterion allow . Glomerular filtration rate ≥ 60 ml/min Subjects childbearing potential must agree use adequate contraception begin sign informed consent form least 3 month last dose study drug . Must able swallow retain oral medication Currently receive systemic therapy metastatic colorectal cancer Previous assignment treatment study . Subjects permanently withdraw study participation allow reenter study . Uncontrolled hypertension despite optimal medical management Active clinically significant cardiac disease . Evidence history bleed diathesis coagulopathy Any hemorrhage bleeding event ≥ grade 3 within 4 week . Subjects thrombotic , embolic , venous , arterial event , cerebrovascular accident , deep vein thrombosis pulmonary embolus within 6 month inform consent History active malignancy within past 2 year . Patients phaeochromocytoma Known history human immunodeficiency virus infection current chronic/active hepatitis B C infection . Ongoing infection &gt; grade 2 Symptomatic metastatic brain meningeal tumor Presence nonhealing wound , nonhealing ulcer , bone fracture Renal failure require hemo peritoneal dialysis Dehydration ≥ grade 1 Patients seizure disorder require medication Persistent proteinuria ≥ grade 3 Interstitial lung disease ongoing sign symptoms time informed consent Pleural effusion ascites cause respiratory compromise , grade 2 dyspnea History organ allograft include corneal transplant Known suspect allergy hypersensitivity study drug Any malabsorption condition Any condition make subject unsuitable trial participation Substance abuse , medical , psychological , social condition may interfere subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>colorectal adenocarcinoma</keyword>
</DOC>